Mangoceuticals (MGRX) EBITDA (2023 - 2026)

Mangoceuticals has disclosed EBITDA across 4 years of filings, most recently posting -$3.4 million for Q1 2026.

• EBITDA for Q1 2026 came in at -$3.4 million, up 29.53% year-over-year; the trailing twelve-month figure through Mar 2026 was -$2.9 million (up 32.75% YoY), and the FY2025 annual result was -$4.3 million, down 137.08% from the prior year.
• EBITDA came in at -$3.4 million for Q1 2026 at Mangoceuticals, down from $13.3 million in the prior quarter.
• In the past five years, EBITDA ranged from a high of $13.3 million in Q4 2025 to a low of -$7.5 million in Q3 2025.
• The 4-year median for EBITDA is -$2.4 million (2024), against an average of -$1.4 million.
• Across the five-year window, EBITDA jumped 273.9% in 2024 and tumbled 329.04% in 2025, its largest moves.
• Mangoceuticals' EBITDA stood at -$2.6 million in 2023, then surged by 273.9% to $4.5 million in 2024, then soared by 198.48% to $13.3 million in 2025, then tumbled by 125.54% to -$3.4 million in 2026.
• The last three EBITDA figures came in at -$3.4 million (Q1 2026), $13.3 million (Q4 2025), and -$7.5 million (Q3 2025), per Business Quant data.